The prospects of pazopanib in advanced renal cell carcinoma. - Wikidata - wikimedia - TriplyDB

The prospects of pazopanib in advanced renal cell carcinoma.

The prospects of pazopanib in advanced renal cell carcinoma.

http://www.wikidata.org/entity/Q34656393

about

The potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapy Therapeutic challenges in renal cell carcinoma ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy Landmarks in the diagnosis and treatment of renal cell carcinoma.Overriding TKI resistance of renal cell carcinoma by combination therapy with IL-6 receptor blockade.HMGB1 promotes myeloid-derived suppressor cells and renal cell carcinoma immune escape.Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies.Sunitinib resistance in renal cell carcinoma.Renal cancer: new models and approach for personalizing therapy

P2860

Q26783291-F5831148-C86F-40C8-8BCB-95E89C03D2A3 Q26796702-46AF2918-D398-4C07-8564-17246EDC1B17 Q35171274-12CC8C7F-8A6A-4432-BA40-5C6539CEB036 Q37620907-1E023A98-F1B5-45FD-AE55-383D99249F4D Q38238966-35E08CB4-1D22-4F79-BB4F-8323BACB3114 Q41549055-977A35B7-BA82-4D13-B04B-C19CBB1C86CF Q42149043-AF3D934B-5DAA-4DD0-A892-5DBDD6E2D92B Q47134647-EB5FF44E-FEFE-4595-B097-013C760834AC Q51763292-F7D592A3-D719-4E0F-8713-D3C02B9158FC Q57160714-D29986F0-DB80-46E8-AB05-6E2B953FA64D

P2860

The prospects of pazopanib in advanced renal cell carcinoma.

http://www.wikidata.org/entity/Q34656393

description

2013 nî lūn-bûn

@nan

2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

The prospects of pazopanib in advanced renal cell carcinoma.

@ast

The prospects of pazopanib in advanced renal cell carcinoma.

@en

The prospects of pazopanib in advanced renal cell carcinoma.

@nl

type

label

The prospects of pazopanib in advanced renal cell carcinoma.

@ast

The prospects of pazopanib in advanced renal cell carcinoma.

@en

The prospects of pazopanib in advanced renal cell carcinoma.

@nl

prefLabel

The prospects of pazopanib in advanced renal cell carcinoma.

@ast

The prospects of pazopanib in advanced renal cell carcinoma.

@en

The prospects of pazopanib in advanced renal cell carcinoma.

@nl

P1433

Q34656393-BB3A6E72-B53A-4D01-A712-5F32575A22E0

P1476

Q34656393-FE7EE1CC-36FA-4082-8404-43F66B372751

P2093

Q34656393-331BC07D-C18D-4023-8E2E-3D8A23D50F33

Q34656393-EF8AC7F1-A3CC-4840-B4DE-55D1678799DA

P2860

Q34656393-03A36447-3FFA-4FEF-9BC5-DD9276283FBD

Q34656393-06C4D68B-66C0-428F-A7F4-DD69ABF339E7

Q34656393-0BC79E9A-104B-4FA4-A6F1-94817E45990E

Q34656393-0F3FF5A3-5C75-4A7A-93B8-7BA7DA260EF9

Q34656393-10D4AE66-6A56-404F-B582-632E0900A7FE

Q34656393-2F451A29-E706-4EBE-9451-CC4F527B7427

Q34656393-334C386B-592D-4CF8-9578-78B5EC62302C

Q34656393-3493AC89-CA04-453D-866B-9C1E9F828D11

Q34656393-3E005B79-886F-4EE7-B1EB-2D41D848ABC6

Q34656393-424266CD-9BE2-4070-AB98-2ECE44AE6392

P304

Q34656393-7D103494-39E3-4614-A2E9-BEA42473F911

P31

Q34656393-815D61A6-CAEF-4AA4-B823-F06498CE644E

P356

Q34656393-0B11A78F-E4F6-428F-A07A-98201947BC41

P433

Q34656393-9613F798-922C-4EEB-8DBA-3DF1AC51DD3D

P478

Q34656393-C9971D00-013B-43E1-949D-F99D495E1869

P577

Q34656393-45AA3F03-C756-4EDD-A1C1-DFEB73665509

P698

Q34656393-D7904EC3-D069-47F2-8968-194E17C4B82E

P932

Q34656393-ADB0810B-6977-4008-9DF9-02BB0AC5C4B6

P356

1756287213495099

P1433

Therapeutic advances in urology

P1476

The prospects of pazopanib in advanced renal cell carcinoma.

@en

P2093

Philippe E Spiess

http://www.w3.org/2001/XMLSchema#string

Shilpa Gupta

http://www.w3.org/2001/XMLSchema#string

P2860

Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Sorafenib in advanced clear-cell renal-cell carcinoma

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

P304

223-232

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1756287213495099

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2013-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24082917

http://www.w3.org/2001/XMLSchema#string

P932

3763778

http://www.w3.org/2001/XMLSchema#string